Skip to content

Study · Non-randomized trial · n = 1,066 · 2003

17 results

Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences.

Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM

Reproductive biomedicine online1 Jun 2003Cited by 25 (Europe PMC)

PMID12831588 (opens in a new tab)DOI10.1016/s1472-6483(10)62163-3 (opens in a new tab)PepBankPUB-12831588
Publisher pagePubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In assisted conception, the multiple-dose cetrorelix group had 251 pregnancies.

    In plain wordsThe multiple-dose cetrorelix group had 251 pregnancies.

    Peptide
    Cetrorelix
    Outcome
    Not applicablePregnancies with multiple-dose protocol
    Study

    n = 1,066

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    Pregnancies
    251 pregnancies
    MD

    Source sentences

    Summary
    A total of 251 and 121 pregnancies were reported in the MD and SD groups respectively.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  2. 02HumanNon-randomized trialEfficacy outcome

    In assisted conception, the single-dose cetrorelix group had 121 pregnancies.

    In plain wordsThe single-dose cetrorelix group had 121 pregnancies.

    Peptide
    Cetrorelix
    Outcome
    Not applicablePregnancies with single-dose protocol
    Study

    n = 541

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mgAs given in this study (human).

    Measurements

    Pregnancies
    121 pregnancies
    SD

    Source sentences

    Summary
    A total of 251 and 121 pregnancies were reported in the MD and SD groups respectively.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  3. 03HumanNon-randomized trialEfficacy outcome

    In assisted conception, seventy-three per cent of the single-dose cetrorelix group received only one injection.

    In plain wordsSeventy-three per cent of the single-dose cetrorelix group received only one injection.

    Peptide
    Cetrorelix
    Outcome
    Not applicableSingle injection requirement
    Study

    n = 541

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mgAs given in this study (human).

    Measurements

    Patients who received only one injection
    73 % of patients
    Single-dose group (3 mg)

    Source sentences

    Summary
    Seventy-three per cent of patients in the SD group received only one injection.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  4. 04HumanNon-randomized trialEfficacy outcome

    In assisted conception, more than 90% of patients on each cetrorelix protocol reached HCG criteria and underwent oocyte retrieval.

    In plain wordsWith either cetrorelix protocol, more than 90% reached HCG criteria and underwent egg retrieval.

    Peptide
    Cetrorelix
    Outcome
    Not applicableHCG criteria and oocyte retrieval
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (multiple-dose protocol) and 3 mg (single-dose protocol)As given in this study (human).

    Measurements

    Patients reaching HCG criteria and undergoing oocyte retrieval
    > 90%
    Cetrorelix protocols

    Source sentences

    Summary
    Patient outcomes were very similar: >90% reached criteria for human chorionic gonadotrophin (HCG) administration and underwent oocyte retrieval;
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  5. 05HumanNon-randomized trialEfficacy outcome

    In assisted conception, embryo transfer occurred in 83-84% with the cetrorelix protocols.

    In plain wordsWith the cetrorelix protocols, embryo transfer occurred in 83-84%.

    Peptide
    Cetrorelix
    Outcome
    Not applicableEmbryo transfer
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (multiple-dose protocol) and 3 mg (single-dose protocol)As given in this study (human).

    Measurements

    Embryo transfer
    83 to 84%
    Cetrorelix protocols

    Source sentences

    Summary
    embryo transfer was performed in 83-84%;
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  6. 06HumanNon-randomized trialEfficacy outcome

    In assisted conception, failure to retrieve oocytes occurred in 0.8% with the cetrorelix protocols.

    In plain wordsWith the cetrorelix protocols, egg retrieval failed in 0.8%.

    Peptide
    Cetrorelix
    Outcome
    Not applicableFailure to retrieve oocytes
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (multiple-dose protocol) and 3 mg (single-dose protocol)As given in this study (human).

    Measurements

    Failure to retrieve oocytes
    0.8%
    Cetrorelix protocols

    Source sentences

    Summary
    failure to retrieve oocytes was rare (0.8%);
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  7. 07HumanNon-randomized trialEfficacy outcome

    In assisted conception, the cetrorelix protocols yielded an average of 11 follicles at least 10 mm wide on the HCG administration day.

    In plain wordsWith the cetrorelix protocols, patients averaged 11 follicles at least 10 mm wide on the HCG administration day.

    Peptide
    Cetrorelix
    Outcome
    Not applicableFollicles at HCG administration
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (multiple-dose protocol) and 3 mg (single-dose protocol)As given in this study (human).

    Measurements

    Mean follicles >=10 mm on day of HCG administration
    11 follicles
    Cetrorelix protocols, average

    Source sentences

    Summary
    on average, 11 follicles > or =10 mm in diameter were seen on the day of HCG administration.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  8. 08HumanNon-randomized trialEfficacy outcome

    In assisted conception, single-dose cetrorelix was associated with more retrieved oocytes than multiple-dose cetrorelix.

    In plain wordsSingle-dose cetrorelix was associated with more retrieved eggs than multiple-dose cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    IncreaseOocytes retrieved
    Study

    n: not reported in source

    Comparator
    Cetrorelix 0.25 mg/day multiple-dose protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg single doseAs given in this study (human).

    Source sentences

    Summary
    The SD protocol was associated with higher numbers of oocytes retrieved and available for insemination, although the numbers of embryos obtained or transferred were comparable.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  9. 09HumanNon-randomized trialEfficacy outcome

    In assisted conception, single-dose cetrorelix was associated with more oocytes available for insemination than multiple-dose cetrorelix.

    In plain wordsSingle-dose cetrorelix was associated with more eggs available for insemination than multiple-dose cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    IncreaseOocytes available for insemination
    Study

    n: not reported in source

    Comparator
    Cetrorelix 0.25 mg/day multiple-dose protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mg single doseAs given in this study (human).

    Source sentences

    Summary
    The SD protocol was associated with higher numbers of oocytes retrieved and available for insemination, although the numbers of embryos obtained or transferred were comparable.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  10. 10HumanNon-randomized trialEfficacy outcome

    In assisted conception, numbers of embryos obtained were comparable between single-dose and multiple-dose cetrorelix.

    In plain wordsNumbers of embryos obtained were comparable between single-dose and multiple-dose cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedEmbryos obtained
    Study

    n: not reported in source

    Comparator
    Multiple-dose versus single-dose cetrorelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (multiple-dose protocol) and 3 mg (single-dose protocol)As given in this study (human).

    Source sentences

    Summary
    The SD protocol was associated with higher numbers of oocytes retrieved and available for insemination, although the numbers of embryos obtained or transferred were comparable.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  11. 11HumanNon-randomized trialEfficacy outcome

    In assisted conception, numbers of embryos transferred were comparable between single-dose and multiple-dose cetrorelix.

    In plain wordsNumbers of embryos transferred were comparable between single-dose and multiple-dose cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedEmbryos transferred
    Study

    n: not reported in source

    Comparator
    Multiple-dose versus single-dose cetrorelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day (multiple-dose protocol) and 3 mg (single-dose protocol)As given in this study (human).

    Source sentences

    Summary
    The SD protocol was associated with higher numbers of oocytes retrieved and available for insemination, although the numbers of embryos obtained or transferred were comparable.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  12. 12HumanNon-randomized trialEfficacy outcome

    In assisted conception, pregnancy per embryo transfer was 27% with multiple-dose cetrorelix.

    In plain wordsPregnancy per embryo transfer was 27% with multiple-dose cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    Not applicablePregnancy rate per embryo transfer with multiple-dose protocol
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    Pregnancy per embryo transfer
    27%
    MD

    Source sentences

    Summary
    Pregnancy rates per embryo transfer were 27 and 28% respectively.
    2 context sentences
    Summary · context
    A total of 251 and 121 pregnancies were reported in the MD and SD groups respectively.
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  13. 13HumanNon-randomized trialEfficacy outcome

    In assisted conception, pregnancy per embryo transfer was 28% with single-dose cetrorelix.

    In plain wordsPregnancy per embryo transfer was 28% with single-dose cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    Not applicablePregnancy rate per embryo transfer with single-dose protocol
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3 mgAs given in this study (human).

    Measurements

    Pregnancy per embryo transfer
    28%
    SD

    Source sentences

    Summary
    Pregnancy rates per embryo transfer were 27 and 28% respectively.
    2 context sentences
    Summary · context
    A total of 251 and 121 pregnancies were reported in the MD and SD groups respectively.
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  14. 14HumanNon-randomized trialSafety outcome

    In assisted conception, severe OHSS occurred in less than 1% of cycles with the cetrorelix protocols.

    In plain wordsSevere ovarian hyperstimulation occurred in less than 1% of cycles with the cetrorelix protocols.

    Peptide
    Cetrorelix
    Outcome
    Not applicableSevere OHSS
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Severe OHSS
    < 1 % of cycles
    Cetrorelix protocols

    Source sentences

    Summary
    Severe ovarian hyperstimulation syndrome (OHSS) occurred in <1% of cycles.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  15. 15HumanNon-randomized trialSafety outcome

    In assisted conception, local injection reactions affected twelve per cent with multiple-dose cetrorelix versus 8% with single-dose cetrorelix.

    In plain wordsLocal injection reactions affected twelve per cent with multiple-dose cetrorelix versus 8% with single-dose cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    IncreaseInjection reactions
    Study

    n: not reported in source

    Comparator
    Single-dose cetrorelix
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    Local injection reactions
    12 % of patients
    Multiple-dose group (0.25 mg/day)
    Local injection reactions
    8 % of patients
    Single-dose group (3 mg)

    Source sentences

    Summary
    Twelve per cent of patients reported local reactions to injections in the MD group, compared with 8% in the SD group; none was serious or led to discontinuation.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  16. 16HumanNon-randomized trialSafety outcome

    In assisted conception, no local injection reaction with the cetrorelix protocols was serious.

    In plain wordsNo local injection reaction with the cetrorelix protocols was serious.

    Peptide
    Cetrorelix
    Outcome
    Not applicableSerious local reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Twelve per cent of patients reported local reactions to injections in the MD group, compared with 8% in the SD group; none was serious or led to discontinuation.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.
  17. 17HumanNon-randomized trialSafety outcome

    In assisted conception, no local injection reaction with the cetrorelix protocols led to discontinuation.

    In plain wordsNo local injection reaction with the cetrorelix protocols led to treatment discontinuation.

    Peptide
    Cetrorelix
    Outcome
    Not applicableDiscontinuation from local reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Twelve per cent of patients reported local reactions to injections in the MD group, compared with 8% in the SD group; none was serious or led to discontinuation.
    1 context sentence
    Summary · context
    Two studies assessed two administration regimens for cetrorelix (as Cetrotide): the multiple-dose (MD, 0.25 mg/day, n = 1066) and single-dose (SD, 3 mg, n = 541) protocols.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.